U.S. public companies lost an average of 1.06% of their annual revenue to known frauds last year, amounting to billions of dollars, according to a new report.
As the nature and frequency of tax reporting changes, organizations are being promised long-term simplification, but are facing an immediate spike in complexity.
The International Ethics Standards Board for Accountants weighed in on private equity investment in accounting firms and ethical and independence concerns.
The American Institute of CPAs supports a bill to allow survivors of domestic abuse or spousal abandonment to file their taxes as if they weren’t married.
Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase III ARISE study, which earlier this year failed to demonstrate significant symptom improvement.
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter earnings call. The partnered Alzheimer’s drug Leqembi saw sales climb 20% for the period.
Employed biopharma professionals are highly likely to look for new jobs in the next 12 months, although not quite as likely as their unemployed counterparts, according to a BioSpace LinkedIn poll. Three recruitment experts discuss the findings and what’s driving job searches.